ArticleScientific reports2025
Predictive risk-scoring model for lateral lymph node metastasis in papillary thyroid carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Clinicopathologic Predictors and Nodal Burden Pattern of Skip Metastasis in Papillary Thyroid Carcinoma: A Multicenter Study.Head & neck · 2026Article
- Development and validation of a multivariable prediction model for lateral lymph node metastasis in papillary thyroid carcinoma.Gland surgery · 2026Article
- Comprehensive analysis of carotid triangle lymph node metastasis in papillary thyroid carcinoma.Frontiers in endocrinology · 2026Article
- Development and validation of a preoperative nomogram for predicting contralateral occult carcinoma and central lymph node metastasis in T1b-T2 stage papillary thyroid carcinoma.Frontiers in endocrinology · 2026Article
- Posterior minimal extrathyroidal extension as an independent risk factor for lateral lymph node metastasis in papillary thyroid carcinoma: a retrospective study based on a nomogram prediction model.Frontiers in endocrinology · 2026Article
- CENPM as a biomarker and therapeutic target for lymph node metastasis in thyroid carcinoma.Frontiers in genetics · 2026Article
- An interpretable machine learning-based approach: development, validation, and clinical utility for distant metastasis prediction in PTC.Frontiers in endocrinology · 2026Article
- Bioinformatics analysis reveals C5AR1's impact on thyroid cancer development via immune infiltration.Scientific reports · 2025Article
- Personalized prediction of lymph node metastasis in papillary thyroid microcarcinoma: a nomogram and web calculator.Scientific reports · 2025Article
- Development of a carbon nanoparticle-guided nomogram for predicting lateral cervical lymph node metastasis in clinically node-negative papillary thyroid carcinoma.American journal of translational research · 2025Article
- Risk factors for predicting lateral lymph node metastasis of papillary thyroid carcinoma based on LASSO-logistic regression.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
This study aims to evaluate candidate risk factors for lateral lymph node metastasis (LLNM) and develop a predictive model to identify high-risk groups among patients with papillary thyroid carcinoma (PTC). Additionally, we identified risk factors for recurrence to inform postoperative therapeutic decisions and follow-up for physicians and patients. A total of 4107 patients (4884 lesions) who underwent lymph node dissection at our hospital from 2005 to 2014 were evaluated. LLNM risk was stratified, and a risk-scoring model was developed based on identified independent risk factors for LLNM. Cox's proportional hazards regression model was used to investigate the risk factors for recurrence. Lateral Lymph Node (LLN) metastasis was observed in 10.49% (431/4107) of patients. Multivariate analysis identified the following independent risk predictors for LLN metastasis: Age ≤ 35 years (P = 0.002), tumor size > 1.0 cm (P = 0.000), lobe dissemination (+) (P = 0.000), and CLNM (+) (P = 0.000). A 12-point risk-scoring model was constructed to predict stratified LLNM in PTC patients, with an area under the receiver operating characteristic curve (AUROC) of 0.794 (95% CI: 0.774-0.814) (P < 0.01). The Cox regression model indicated that tumor size > 1.0 cm, lobe dissemination (+), multifocality, Central Lymph Node Metastasis (CLNM), and LLNM were significant risk factors associated with poor outcomes. Based on the risk scoring model, additional investigations and comprehensive considerations are recommended for patients with a total score greater than 5, and prophylactic cervical lymph node dissection is performed if necessary. Additionally, more aggressive treatment and more frequent follow-ups should be considered for patients with tumor size > 1.0 cm, lobe dissemination (+), multifocality, CLNM, and LLNM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.